^
9ms
Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma. (PubMed, Transl Cancer Res)
By means of oncoPredict, MG-132, BMS-536924, PLX-4720, and AZD6482 were identified as potential sensitive drugs for high-risk patients, of which MG-132 was particularly recommended for high-risk patients. We performed in vitro experiments to explore the anti-glioma effect of MG-132, and the results demonstrated MG-132 could inhibit the proliferation and migration of glioma cells. Our findings show that CCC genes are associated with the prognosis and immune infiltration of LGG and provide possible immunotherapeutic and novel chemotherapeutic strategies for patients with LGG based on the risk signature.
Journal • IO biomarker
|
SERPINA1 (Serpin Family A Member 1)
|
PLX4720 • AZD6482 • MG132 • BMS-536924
11ms
A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma. (PubMed, Aging (Albany NY))
Furthermore, high-risk DLBCL patients exhibited increased sensitivity to bortezomib, rapamycin, AZD6244, and BMS.536924, while low-risk DLBCL patients showed sensitivity to cisplatin and ABT.263. Using RT-qPCR, we found that three protective model genes, namely TCEAL7, EPHA4, and ELOVL4, were down-regulated in DLBCL tissues compared with control tissues. In conclusion, our novel TRGs-based model has great predictive value for the prognosis of DLBCL patients and provides a promising direction for treatment optimization.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • EPHA4 (EPH Receptor A4)
|
cisplatin • Koselugo (selumetinib) • bortezomib • sirolimus • navitoclax (ABT 263) • BMS-536924
over1year
PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. (PubMed, World J Surg Oncol)
The PI3K pathway mutation status could be considered as a potential biomarker to predict better immunotherapeutic efficacy and clinical outcomes after immunotherapy in HNSC patients.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
PLX4720 • TAE-684 • linsitinib (ASP7487) • BMS-536924
almost2years
Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer. (PubMed, Aging (Albany NY))
We successfully established and verified a novel circadian clock-related gene signature, which could stratify patients with different risk and be reflective of the therapeutic effect of molecular targeted therapy. Our findings could incorporate the pharmacological modulation of circadian clock into future therapeutic strategies.
Journal
|
CD8 (cluster of differentiation 8) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • CDK1 (Cyclin-dependent kinase 1) • KLF10 (Kruppel Like Factor 10)
|
erlotinib • linsitinib (ASP7487) • foretinib (GSK1363089) • BMS-536924 • sabutoclax (ONT-701)
over2years
CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. (PubMed, Mol Cancer)
CircVAPA promotes SCLC progression via the miR-377-3p and miR-494-3p/IGF1R/AKT axis. We hope to develop clinical protocols of combinations of circVAPA inhibition and BMS-536924 addition for treating SCLC with circVAPA upregulation.
Journal
|
MIR494 (MicroRNA 494)
|
BMS-536924
almost3years
An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma. (PubMed, Front Pharmacol)
We found that the high-risk group had higher frequencies of KRAS, TP53, and CDKN2A mutations, increased infiltration of macrophages M0, neutrophils, and macrophages M2 cells, as well as upregulated hypoxia and glycolysis pathways, while the low-risk group had increased infiltration of CD8 T, naïve B, and plasma and macrophages M1 cells. We constructed and validated an IRRGs signature that could be used to predict the prognosis and gemcitabine response of patients with PDAC, as well as two drugs (BMS-536924 and dasatinib) may contribute to PDAC treatment.
Clinical • Journal • Gene Signature
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • EREG (Epiregulin) • ITGA5 (Integrin Subunit Alpha 5)
|
TP53 mutation • CDKN2A mutation
|
dasatinib • gemcitabine • BMS-536924
4years
ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. (PubMed, Front Genet)
ATM mutations resulted in increased bladder cancer sensitivity to 29 drugs (P < 0.05), including cisplatin and BMS-536924, an IGF-1R inhibitor. Our results demonstrate the importance of ATM as a prognostic signature in bladder cancer and reveal that ATM may impact the effects of ICIs by acting on the tumor immune microenvironment.
Clinical • Journal • Checkpoint inhibition • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase)
|
ATM mutation
|
cisplatin • BMS-536924